Skip to main content
OpenTrials
Completed

NCT Number: NCT02756702

All Polyethylene Tibia-VEGA Kiel

Obligatory Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation For this PMCF only CE-marked medical devices will be used within their intended purpose and no additional invasive or other stressful examinations are to be carried out (acc. to MPG §23b).

Completed

Looking for future studies?

Notify Me

Key information

About this study

This non-interventional clinical study (NIS) is conducted to clinically confirm the safety and performance of the Aesculap® APT VEGA System® PS components under routine conditions. The VEGA System® PS is an established TKA design, and there is a long-lasting experience in the use of PE for TKA in general and for APT components in particular; thus a NIS is thought to be sufficient to give the required confirmation. For this NIS only CE-marked medical devices will be used within their intended purpose and no additional invasive or other stressful examinations are to be carried out (acc. to MPG §23b). As part of the post marketing surveillance plan an obligatory Post-Marketing Clinical Follow-up (PMCF) is required for the product under investigation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients requiring primary TKA because of severe knee joint conditions that cannot be treated through other therapies;
  • degenerative osteoarthritis;
  • rheumatoid arthritis;
  • posttraumatic arthritis;
  • symptomatic knee instability;
  • knee stiffness or deformation of the knee joint;
  • Age ≥ 18 years;
  • Patient signed informed consent

Exclusion criteria

  • Age younger than 18 years
  • Any prior joint replacement at the index knee
  • Unable or unwilling to return for postoperative follow-up
  • Patient did not sign informed consent
  • Joint conditions that can be treated by reconstructive surgery (e.g. osteotomy)
  • Acute or chronic infections near the joint, or systemic infections
  • Secondary diseases that could influence joint implant functionality
  • Systemic diseases and metabolic disorders
  • Severe osteoporosis or osteomalacia
  • Severely damaged bone structures that could prevent stable implantation of implant components
  • Bone tumors in the region of implant fixation
  • Bone malformations, axial misalignments or other bone conditions that rule out implantation of a prosthetic joint
  • Expected overload on the joint implant, especially due to high patient weight or intense physical strain and activity
  • Dependency on pharmaceutical drugs, drug abuse, or alcoholism
  • Fever, infection or inflammation (systemic or local)
  • Pregnancy
  • Mental illness
  • Severe osteopenia (or any other medical or surgical finding) that would preclude any benefit from the implants
  • Combination with implant components from other manufacturers
  • Inadequate patient compliance
  • Foreign body sensitivity to the implant materials
  • All cases not listed under indications

Treatment and study plan

All-Poly

Device

Implantation of the VEGA PS using all-polyethylene tibia components

Other names: Total Knee Replacement

Primary outcomes

  1. Revision Rate

    Time frame: 5 years

    The objective of the study is to collect clinical midterm outcome information on the product under investigation when used in routine clinical practice.

Secondary outcomes

  1. Complication/Adverse Event rate

    Time frame: 5 years

    Cumulative Number of Complications / Adverse Events of any reason over the period of follow-up

  2. KOOS (Knee Osteoarthritis Outcome Score)

    Time frame: 5 years

    Changes of the total Knee injury and Osteoarthritis Outcome Score (KOOS) from the preoperative baseline to the 5-year postoperative

  3. KSS (Knee Society Score)

    Time frame: 5 years

    Changes of the Knee Society Score (KSS) with its Knee and Functional Score (KS and FS) from the preoperative baseline to the 5-year postoperative assessment

  4. SF-12® Health Survey (SF-12)

    Time frame: 5 years

    Changes of the total SF-12® Health Survey (SF-12) components Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) from the preoperative baseline to the 5-year postoperative assessment

  5. Change of anterior knee pain over follow-up period

    Time frame: 5 years

    Changes of anterior knee pain according to the Waters and Bentley rating system from the preoperative baseline to the 5-year postoperative assessment

Sponsors and collaborators

Lead sponsor

Aesculap AG

Industry

Collaborators

  • Frictionless GmbH, Kiel

Registry information

Official study title

Prospective Observational 5 Year Follow-up on a Consecutive Cohort of 70 Primary Total Knee Arthroplasty (TKA) Cases Treated With All-polyethylene Tibia (APT) Components of the Posterior-stabilized VEGA System PS

Acronym: APT-VEGA_KI

Important dates

Study start
2016
Primary completion
2017
Study completion
2022
First posted
Apr 29, 2016
Registry last updated
Jun 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.